Price erosion in the US market dented Alembic Pharmaceuticals Limited in the fiscal second quarter, with a compliance “re-verification” visit at an Indian site by the US Food and Drug Administration that did not end up with an all-clear adding to the short-term challenges for the Indian company.
US Price Erosion Dents Alembic
Site Re-Inspection Springs Fresh Challenge As Company Remains Bullish Overall On US
Challenging phase for Alembic as continued price erosion in the US hurts earnings, while a compliance re-inspection by the FDA at an injectables site results in 10 observations. Investors believe US sales may have bottomed out at current levels but can the Indian firm bounce back quickly?
More from Earnings
More from Business
• By
Generics Bulletin previews the most noteworthy and anticipated events for May 2025.
• By
Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.
• By
Reflecting increased regulatory pressure and a wider drive towards the reshoring of pharmaceutical manufacturing to the US, Speranza has launched a new generics business called Lotus Therapeutics.